Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(21)
•••
Comment by Jaaghosnon Apr 25, 2020 8:56am
301 Views
Post# 30952812

RE:RE:RE:RE:RE:Don’t Skin Me Alive MugsMods

RE:RE:RE:RE:RE:Don’t Skin Me Alive MugsModsGreat post! Just want to add 2 things.

1. Antibe has a patent for their medicines that will last 7 and a half years in USA and 10 years in Europe. 

2. Their patent is for their medicine NOT for hydrogen sulfide as a whole. Dan Legault mentioned this in his interview on Biopub.co...  
He then went on to say they are a full decade ahead of any other competitor. 

Overall, Antibe has such a significant start ahead of the next competitor, that they will make 10s of billions before someone rips them off in 7 and a half years. If anyone Ian wondering by why they patented their medicines and not hydrogen sulfide, it’s becuse they wanted a stronger patent. Trying to patent hydrogen sulfide by as whole would Ben too difficult. Antibe definitely made the right choice by protecting their medicines considering the heads start they have. They will make 10s of billions off of ATB pipeline. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities